Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Journal of Clinical Oncology

• Publication date

  2011-06-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2010.33.3179PMID 21606426PMCID PMC3138633
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Treatment Interruptions and Non-Adherence with Imatinib and Associated Healthcare Costs

  2012cited by this paper
• Mobile phone technologies improve adherence to antiretroviral treatment in a resource-limited setting: a randomized controlled trial of text message reminders

  2011influential reference
• Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer

  2011cited by this paper
• Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients.

  2010cited by this paper
• Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104.

  2010cited by this paper
• Thinking outside the pillbox--medication adherence as a priority for health care reform.

  2010cited by this paper
• Individual patients hold different beliefs to prescription medications to which they persist vs nonpersist and persist vs nonfulfill

  2010cited by this paper
• American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.

  2010cited by this paper
• American society of clinical oncology clinical practice guideline update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.

  2010cited by this paper
• Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy.

  2010cited by this paper
• P4P4P: an agenda for research on pay-for-performance for patients.

  2009cited by this paper
• A review of interventions used to improve adherence to medication in older people.

  2009cited by this paper
• Impact of a Prescription Copayment Increase on Lipid-Lowering Medication Adherence in Veterans

  2009cited by this paper
• Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study.

  2009cited by this paper
• Increase in oral cancer drugs raises thorny issues for oncology practices.

  2009cited by this paper
• Predictors of first-fill adherence for patients with hypertension.

  2009cited by this paper
• Patient adherence and persistence with oral anticancer treatment

  2009cited by this paper
• Interventions to improve medication adherence among older adults: meta-analysis of adherence outcomes among randomized controlled trials.

  2009cited by this paper
• The development of an objective methodology to measure medication adherence to oral thiopurines in paediatric patients with acute lymphoblastic leukaemia—an exploratory study

  2009cited by this paper
• Adjuvant hormonal therapy use among insured, low-income women with breast cancer.

  2009cited by this paper
• Pharmaceutical policies: effects of cap and co-payment on rational drug use.

  2008cited by this paper
• Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer

  2008cited by this paper
• Psychosocial Influences on Suboptimal Adjuvant Breast Cancer Treatment Adherence Among African American Women: Implications for Education and Intervention

  2008cited by this paper
• Interventions designed to improve the quality and efficiency of medication use in managed care: A critical review of the literature – 2001–2007

  2008cited by this paper
• A test of financial incentives to improve warfarin adherence

  2008cited by this paper
• Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer.

  2008cited by this paper
• Insight into barriers against optimal adherence to oral hormonal therapy in women with breast cancer.

  2008cited by this paper
• Mortality impact of less-than-standard therapy in older breast cancer patients.

  2008cited by this paper
• 4–48 Early Discontinuation of Tamoxifen: A Lesson for Oncologists

  2008cited by this paper
• Interventions for enhancing medication adherence (Review)

  2008cited by this paper
• Interventions for enhancing medication adherence.

  2008cited by this paper
• The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP.

  2007cited by this paper
• Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen Alone or in Combination) trial

  2007cited by this paper
• Prescription drug cost sharing: associations with medication and medical utilization and spending and health.

  2007cited by this paper
• Early discontinuation of tamoxifen

  2007cited by this paper
• Adherence to tamoxifen over the five-year course

  2006cited by this paper
• Methods for evaluation of medication adherence and persistence using automated databases

  2006cited by this paper
• Measurement of Adherence in Pharmacy Administrative Databases: A Proposal for Standard Definitions and Preferred Measures

  2006cited by this paper
• Randomized trial of long-term follow-up for early-stage breast cancer: a comparison of family physician versus specialist care.

  2006cited by this paper
• Randomized trial of long-term follow-up for early-stage breast cancer: a comparison of family physician versus specialist care.

  2006cited by this paper
• Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

  2005cited by this paper
• Effects of the increase in co-payments from 20 to 30 percent on the compliance rate of patients with hypertension or diabetes mellitus in the Employed Health Insurance System

  2005cited by this paper
• Adherence beliefs among breast cancer patients taking tamoxifen.

  2005cited by this paper
• Adherence to medication.

  2005cited by this paper
• Adherence to medication.

  2005cited by this paper
• Intentional and non-intentional non-adherence to medication amongst breast cancer patients.

  2005cited by this paper
• Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor--positive breast cancer.

  2004cited by this paper
• Pharmacy benefits and the use of drugs by the chronically ill.

  2004cited by this paper
• EFFECTS OF AN INCREASE IN PATIENT COPAYMENTS ON MEDICAL SERVICE DEMANDS OF THE INSURED IN JAPAN

  2003cited by this paper
• Implementation Brief: A Two-way Messaging System to Enhance Antiretroviral Adherence

  2003influential reference
• Retrospective, long-term follow-up study of the effect of a three-tier prescription drug copayment system on pharmaceutical and other medical utilization and costs.

  2003cited by this paper
• Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer.

  2003cited by this paper
• Follow-up of breast cancer in primary care vs specialist care: results of an economic evaluation

  1999cited by this paper
• Comparison of breast cancer patient satisfaction with follow-up in primary care versus specialist care: results from a randomized controlled trial.

  1999cited by this paper
• The effect of increased prescription drug cost-sharing on medical care utilization and expenses of elderly health maintenance organization members.

  1997cited by this paper
• Episode treatment groups: an illness classification and episode building system--Part I.

  1996cited by this paper
• Episode treatment groups: an illness classification and episode building system--Part II.

  1996cited by this paper
• Episode treatment groups: an illness classification and episode building system--Part II.

  1996cited by this paper
• Routine follow up of breast cancer in primary care: randomised trial

  1996cited by this paper
• The effect of prescription size on acquisition of maintenance medications

  1993cited by this paper
• The Effect of Drug Co-Payments on Utilization and Cost of Pharmaceuticals in a Health Maintenance Organization

  1990cited by this paper

• Financial Toxicity, Hope, and Satisfaction With Life in Patients Receiving Ambulatory Cancer Care

  2026cites this paper
• Determinants of Oral Chemotherapy Adherence: A Social Cognitive Perspective

  2025cites this paper
• Extended endocrine therapy use and decision making after breast cancer diagnosis.

  2025cites this paper
• Cost of Convenience in Cancer Care.

  2025cites this paper
• Promoting equitable access to financial services to end financial discrimination against cancer survivors in Europe: scientific and ethical reasons

  2025cites this paper
• Racial and Rural Disparities in Financial Toxicity and Healthcare Transitions Among Adolescent and Young Adult Cancer Survivors in Kentucky: A Cross-Sectional Study

  2025cites this paper
• Psychosocial aspects of quality of life outcomes in post-treatment human papillomavirus-associated cancer survivors in the United States: A scoping review

  2025cites this paper
• Double burden: financial toxicity in patients with advanced soft tissue sarcoma at the start of first-line palliative chemotherapy: baseline data from the HOLISTIC study

  2025cites this paper
• A Scoping Review of Interventions to Address Financial Toxicity in Pediatric and Adult Patients and Survivors of Cancer

  2025cites this paper
• Psychometric properties of instruments for assessing adherence to oral antineoplastic agents: a COSMIN systematic review

  2025cites this paper
• Social Support, Quality of Life, and Financial Toxicity Among Patients with Hepatocellular Carcinoma

  2025cites this paper
• Addressing Health Equity, Diversity, and Inclusion in the Bleeding Disorders Community: Insights From a Pilot Study of Multi‐Stakeholder Interviews and Survey Data

  2025cites this paper
• Impact of Reaching the Medicare Part D Drug Benefit Threshold on Surgical Care and Health Outcomes Among Patients Newly Diagnosed With Gastrointestinal Cancer

  2025cites this paper
• Novel Survivorship Paradigms in Head/Neck Cancer.

  2025cites this paper
• Hidden Costs of Endocrine Therapy for Black Breast Cancer Survivors: A Qualitative Examination of Patient and Provider Experiences.

  2025cites this paper
• Adherence to Adjuvant Endocrine Therapy in Patients With Nonmetastatic Estrogen Receptor–Positive Breast Cancer: A Comprehensive Brazilian Real-World Data Study

  2025cites this paper
• Financial hardship, financial toxicity, and transportation challenges among older cancer survivors treated with curative-intent surgery

  2025cites this paper
• The financial toll of cancer: uncovering the links between financial toxicity and symptom burden

  2025cites this paper
• Understanding financial toxicity in health care: voices of patients, hospitals and NGOs – empowering recovery through financial support

  2025cites this paper
• Implementing motivational interviewing to improve endocrine therapy adherence among breast cancer patients: a qualitative process evaluation of the getset pilot intervention

  2025cites this paper
• Drivers of Job Loss Among Chinese Breast Cancer Survivors: A Qualitative Analysis

  2025cites this paper
• Financial Toxicity Among Patients with Peripheral Artery Disease.

  2025cites this paper
• Differences in GLP-1 RA medication adherence across place-based variables in patients with diabetes living in Wisconsin.

  2025cites this paper
• Adherence to intravenous chemotherapy and associated factors among patients with cancer at Hawassa University Comprehensive Specialized Hospital Cancer Treatment Center, Sidama Region, Southern Ethiopia

  2025cites this paper
• Patient Experiences and Preferences Regarding Medication Cost Discussions Among Heart Failure Patients in Singapore: A Qualitative Survey

  2025cites this paper
• Symptom Monitoring App Use Associated With Medication Adherence Among Woman Survivors of Breast Cancer on Adjuvant Endocrine Therapy

  2024cites this paper
• Relationship between nurses' perceptions and financial toxicity management in the public health insurance system.

  2024cites this paper
• Financial Improvements From Short Course Adjuvant Vaginal Cuff Brachytherapy in Early Endometrial Cancer Compared With Standard of Care, "SAVE" Trial.

  2024cites this paper
• Risk of Financial Toxicity Among Adults Undergoing Lung and Esophageal Resections for Cancer.

  2024cites this paper
• Financial Toxicity in High-Grade Glioma Resection: A Retrospective Analysis.

  2024cites this paper
• Breast cancer survivors’ opinion on personalizing endocrine therapy and developing informative tools

  2024cites this paper
• Interventions to Mitigate Financial Toxicity in Adult Patients with Cancer in the United States: A Scoping Review

  2024cites this paper
• Toward identification and intervention to address financial toxicity and unmet health‐related social needs among adolescents and emerging adults with cancer and their caregivers: A cross‐cultural perspective

  2024cites this paper
• Treatment Cost and Psychological Impact of Burkitt Lymphoma on Ghanaian Families and Caregivers.

  2024cites this paper
• Chinese expert consensus on an innovative patient‐centered approach to diagnosis and treatment of cancer

  2024cites this paper
• Patient perceptions of copay card utilization and policies

  2023cites this paper
• Concomitant Discontinuation of Cardiovascular Therapy and Adjuvant Hormone Therapy Among Patients With Breast Cancer

  2023cites this paper
• Breast cancer treatment receipt and the role of financial stress, health literacy, and numeracy among diverse breast cancer survivors

  2023cites this paper
• Impact of initiating oral anticancer agents for leukemia on adherence to medications for multiple chronic conditions

  2023cites this paper
• Randomized phase III trial evaluating motivational interviewing and text interventions to optimize adherence to breast cancer endocrine therapy (Alliance A191901): the GETSET protocol

  2023cites this paper
• Out-of-Pocket Costs of Treatment Among Employer-Insured Women With Invasive Breast Cancer

  2023cites this paper
• Financial toxicity of oral therapies in advanced prostate cancer.

  2023cites this paper
• Discussing Cost and Value in Patient Decision Aids and Shared Decision Making: A Call to Action

  2023cites this paper
• Investigation of Factors Affecting Adherence to Adjuvant Hormone Therapy in Early-Stage Breast Cancer Patients: A Comprehensive Systematic Review

  2023cites this paper
• Factors Influencing the Continuation of Work in Patients with Cancer Willing to Work: An Exploratory Study

  2023cites this paper
• Administrative Burden Associated with Cost-Related Delays in Care in U.S. Cancer Patients.

  2023cites this paper
• Financial Toxicity in Breast Implant–Associated Anaplastic Large Cell Lymphoma

  2023cites this paper
• OncotypeDX Testing Does Not Benefit Patients with Estrogen and Progesterone Receptor Positive Grade 1 Breast Cancers: A TAILORx Validated Study.

  2023cites this paper
• From Race to Racism and Disparities to Equity

  2023cites this paper
• Financial Toxicity Intervention Improves Outcomes in Patients With Hematologic Malignancy

  2022cites this paper
• Impact of the Drug Prices Control Order (2013) on the Utilization of Anticancer Medicines in India: An Interrupted Time-Series Analysis

  2022cites this paper
• Prescription drug coverage satisfaction and medication nonadherence among Medicare beneficiaries with cancer

  2022cites this paper
• Personalizing Adjuvant Endocrine Therapy for Early-Stage Hormone Receptor-Positive Breast Cancer.

  2022cites this paper
• Network Modeling of Complex Time-Dependent Changes in Patient Adherence to Adjuvant Endocrine Treatment in ER+ Breast Cancer

  2022cites this paper
• Medication delivery factors and adjuvant endocrine therapy adherence in breast cancer

  2022cites this paper
• How Do You DISCO? Leveraging the Discussions of Cost App to Reduce Financial Toxicity and Improve Treatment Cost Communication

  2022cites this paper
• Survival disparities among non-elderly American adults with locally advanced gastric cancer undergoing gastrectomy by health insurance status.

  2022cites this paper
• The relationship among psychosocial adaptation, medication adherence and quality of life in breast cancer women with adjuvant endocrine therapy

  2022cites this paper
• Assessment of Racial Disparity in Survival Outcomes for Early Hormone Receptor-Positive Breast Cancer After Adjusting for Insurance Status and Neighborhood Deprivation: A Post Hoc Analysis of a Randomized Clinical Trial.

  2022cites this paper
• Drivers of racial, regional, and socioeconomic disparities in late‐stage breast cancer mortality

  2022cites this paper
• Cost-sharing and adherence, clinical outcomes, health care utilization, and costs: A systematic literature review

  2022cites this paper
• Patient, provider, and hospital factors associated with oral anti-neoplastic agent initiation and adherence in older patients with metastatic renal cell carcinoma.

  2022cites this paper
• Availability and Accessibility of Cancer Care Delivery Approaches to Reduce Financial Toxicity of Rural and Urban Cancer Patients in Kentucky.

  2022cites this paper
• Assessment of Oncology Patient Engagement and Interest in Virtual Mind-Body Programming: Moving Toward Personalization of Virtual Care

  2022cites this paper
• Association of Adherence to Endocrine Therapy Among Patients With Breast Cancer and Potential Drug-Drug Interactions

  2022cites this paper
• The Landmark Series—Addressing Disparities in Breast Cancer Screening: New Recommendations for Black Women

  2022cites this paper
• The Role of Cryoablation in Breast Cancer Beyond the Oncologic Control: COST and Breast-Q Patient-Reported Outcomes

  2022cites this paper
• Financial Burden in Blood or Marrow Transplantation Survivors During the COVID-19 Pandemic: A BMTSS Report

  2022cites this paper
• Pilot Study in Investigating Material Financial Toxicity Markers by Age in Cancer Patients

  2022cites this paper
• Enhancing access to and diversity in cancer clinical trials through a financial reimbursement program: Protocol to evaluate a novel program.

  2022cites this paper
• Out-of-Pocket Cost Burden Associated With Contemporary Management of Advanced Prostate Cancer Among Commercially Insured Patients

  2022cites this paper
• Financial worry in people with cancer: Relationship to employment and outcomes

  2022cites this paper
• Shared burden: the association between cancer diagnosis, financial toxicity, and healthcare cost-related coping mechanisms by family members of non-elderly patients in the USA

  2022cites this paper
• Medication Non-Adherence in Rheumatology, Oncology and Cardiology: A Review of the Literature of Risk Factors and Potential Interventions

  2022cites this paper
• Financial Toxicity in the Post-Health Reform Era.

  2022cites this paper
• Maintenance Capecitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma-Magic Bullet or Pandora's Box?

  2022cites this paper
• How palliative care teams can mitigate financial toxicity in cancer care

  2021cites this paper
• Cost sharing for breast cancer hormone therapy: How do dual eligible patients’ copayment impact adherence

  2021cites this paper
• The DISCO App: Evaluating an Electronic Patient Intervention to Reduce The Financial Burden of Cancer Through Improved Cost Communication In A Non-Randomized Pilot Trial

  2021cites this paper
• Cost-effectiveness and drug wastage of immunotherapeutic agents for hematologic malignancies: a systematic review

  2021cites this paper
• Recurrence score testing does not appear to benefit patients with Grade 1, progesterone receptor-positive breast cancers: An opportunity to eliminate overtreatment and decrease testing costs.

  2021cites this paper
• Does Cancer Treatment-Related Financial Distress Worsen Over Time?

  2021cites this paper
• DISCO App: study protocol for a randomized controlled trial to test the effectiveness of a patient intervention to reduce the financial burden of cancer in a diverse patient population

  2021cites this paper
• Impact of employment and insurance status on distress in gynecologic oncology patients.

  2021cites this paper
• Interventions to Improve Adherence to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

  2021cites this paper
• Breast cancer patients' insurance status and residence zip code correlate with early discontinuation of endocrine therapy: An analysis of the ECOG‐ACRIN TAILORx trial

  2021cites this paper
• Immune-Based Cancer Treatment: Addressing Disparities in Access and Outcomes.

  2021cites this paper
• Changes in initiation of adjuvant endocrine therapy for breast cancer after state health reform

  2021cites this paper
• Phase II study of propranolol feasibility with neoadjuvant chemotherapy in patients with newly diagnosed breast cancer

  2021cites this paper
• Investigation of Intervention Solutions to Enhance Adherence to Oral Anticancer Medicines in Adults: Overview of Reviews

  2021cites this paper
• Machine Learning to Predict Tamoxifen Nonadherence Among US Commercially Insured Patients With Metastatic Breast Cancer.

  2021cites this paper
• The global landscape of treatment standards for breast cancer.

  2021cites this paper
• Endocrine therapy and radiotherapy use among older women with hormone receptor-positive, clinically node-negative breast cancer

  2021cites this paper
• The association of health insurance literacy and numeracy with financial toxicity and hardships among colorectal cancer survivors

  2021cites this paper
• Integrating Financial Toxicity Assessment in Cancer Treatment: Implications for Medical Oncology Training

  2021cites this paper
• Assessing the financial toxicity in Tunisian cancer patients using the Comprehensive Score for Financial Toxicity (COST)

  2021cites this paper
• Bankruptcy among insured surgical patients with breast cancer: Who is at risk?

  2021cites this paper
• Initiation and adherence to adjuvant endocrine therapy among urban, insured American Indian/Alaska Native breast cancer survivors

  2021cites this paper
• Interventions to address cancer-related financial toxicity: Recommendations from the field.

  2021cites this paper
• Financial Toxicity in Women with Breast Cancer Receiving Radiotherapy: Final Results of a Prospective Observational Study.

  2021cites this paper